Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN: melflufen + dexamethasone versus pomalidomide + dexamethasone in lenalidomide-refractory relapsed/refractory multiple myeloma
NL-OMON52982Phase 3Completed
- Sponsor
- Oncopeptides AB
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Melflufen + dexamethasone with Pomalidomide + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started May 2018; status: completed.
02
Drugs
melphalan flufenamidepomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON52982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52982.